Risk assessment score for drug eluting stent restenosis
https://doi.org/10.15829/1560-4071-2018-9-23-27
Abstract
Aim. To evaluate most significant risk factors of stent restenosis in coated stents, to develop a logistic model and invent prediction score of restenosis for real clinical practice application.
Material and methods. Totally, 126 patients included, age 40 to 75 y. o. with chronic coronary heart disease, who had undergone repeated coronary arteriography within 6 to 12 month after percutaneous intervention with drug eluting stents implantation. Patients were selected to 2 groups: with restenosis (n=53) and with the none (n=73). Assessment of 35 clinical, laboratory and angiographic properties was done with logistic regression analysis.
Results. There were 4 main risk factors found for restenosis risk: type 2 diabetes, low diameter of stented artery (<2,75 mm), number of simultaneously implanted stents and increased rate of neutrophil to lymphocyte numbers. A logistic model was built that combinates the parameters. ROC-analysis showed high predictive value of the model (square under curve ROC 0,78, p<0,001). Based on the logistic model, a score was invented for prediction of restenosis probability for clinical practice introduction.
Conclusion. The proposed score shows high predictive power and is easy in use, that make it suitable for clinical practice in assessment of the risk of coated stents restenosis.
About the Authors
Z. A. Gabbasov
National Medical Research Center for Cardiology of the Ministry of Health
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
Conflicts of Interest nothing to declare
I. S. Melnikov
National Medical Research Center for Cardiology of the Ministry of Health; Institute of Medical and Biological Issues of RAS
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
Conflicts of Interest nothing to declare
S. V. Byazrova
National Medical Research Center for Cardiology of the Ministry of Health
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
Conflicts of Interest nothing to declare
S. G. Kozlov
National Medical Research Center for Cardiology of the Ministry of Health
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
Conflicts of Interest nothing to declare
References
1. Buccheri D, Piraino D, Andolina G, et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016 Oct;8(10):E1150-E1162. doi:10.21037/jtd.2016.10.93.
2. Alraies MC, Darmoch F, Tummala R, et al. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 2017 Aug 26;9(8):640-51. doi:10.4330/wjc.v9.i8.640.
3. Stolker JM, Kennedy KF, Lindsey JB, et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ Cardiovasc Interv. 2010 Aug;3(4):327-34. doi:10.1161/CIRCINTERVENTIONS.110.946939.
4. Stone GW, Parise H, Witzenbichler B, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2010 Nov 2;56(19):1597-604. doi:10.1016/j.jacc.2010.08.608.
5. Looser PM, Kim LK, Feldman DN. In-Stent Restenosis: Pathophysiology and Treatment. Curr Treat Options Cardiovasc Med. 2016 Feb;18(2):10. doi:10.1007/s11936-015-0433-7.
6. Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014 Aug;32(3):439-55. doi:10.1016/j.ccl.2014.04.001.
7. Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J Atheroscler Thromb. 2018 Jan 1;25(1):27-39. doi:10.5551/jat.RV17014.
8. Uetani T, Amano T, Harada K, et al. Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. JACC Cardiovasc Interv. 2012 Nov;5(11):1159-67. doi:10.1016/j.jcin.2012.07.008.
9. Papa A, Emdin M, Passino C, et al. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta. 2008;395:27-31. doi:10.1016/j.cca.2008.04.019.
10. Uthamalingam S, Patvardhan EA, Subramanian S et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol. 2011 Feb 1;107(3):433-8. doi:10.1016/j.amjcard.2010.09.039.
11. Chavarria N. Elevated Neutrophil-to-lymphocyte ratio is associated with drug eluting stent restenosis. JACC. 2013 Mar 12;61(10):e181. doi:10.1007/s12471-016-0850-6.
Review
For citations:
Gabbasov Z.A., Melnikov I.S., Byazrova S.V., Kozlov S.G. Risk assessment score for drug eluting stent restenosis. Russian Journal of Cardiology. 2018;(9):23-27. (In Russ.) https://doi.org/10.15829/1560-4071-2018-9-23-27
Views:
1206
Email this article 